Head to Head Analysis: LENZ Therapeutics (NASDAQ:LENZ) vs. Fresh Tracks Therapeutics (NASDAQ:FRTX)

LENZ Therapeutics (NASDAQ:LENZ) and Fresh Tracks Therapeutics (NASDAQ:FRTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Earnings & Valuation

This table compares LENZ Therapeutics and Fresh Tracks Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	N/A	N/A	-$124.65 million	N/A	N/A
Fresh Tracks Therapeutics	$10.06 million	0.39	-$5.69 million	($1.41)	-0.46

Fresh Tracks Therapeutics has higher revenue and earnings than LENZ Therapeutics.

Institutional and Insider Ownership

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. 38.4% of LENZ Therapeutics shares are held by company insiders. Comparatively, 0.2% of Fresh Tracks Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

LENZ Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Profitability

This table compares LENZ Therapeutics and Fresh Tracks Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-58.48%	-55.50%
Fresh Tracks Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for LENZ Therapeutics and Fresh Tracks Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	0	0	6	1	3.14
Fresh Tracks Therapeutics	0	0	0	0	0.00

LENZ Therapeutics currently has a consensus target price of $35.40, suggesting a potential upside of 52.59%. Given LENZ Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe LENZ Therapeutics is more favorable than Fresh Tracks Therapeutics.

Summary

LENZ Therapeutics beats Fresh Tracks Therapeutics on 7 of the 11 factors compared between the two stocks.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

About Fresh Tracks Therapeutics

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.